Jiang YL, Fu XY, Yin ZH. Retrospective efficacy analysis of olaparib combined with bevacizumab in the treatment of advanced colorectal cancer. World J Gastrointest Surg 2023; 15(5): 906-916 [PMID: 37342840 DOI: 10.4240/wjgs.v15.i5.906]
Corresponding Author of This Article
Zhi-Hui Yin, MM, Associate Chief Physician, Department of Anorectal, The First Affiliated Hospital, Hengyang Medical School, University of South China, No. 69 Chuanshan Avenue, Shigu District, Hengyang 421001, Hunan Province, China. yinzhihui6996@163.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Surg. May 27, 2023; 15(5): 906-916 Published online May 27, 2023. doi: 10.4240/wjgs.v15.i5.906
Retrospective efficacy analysis of olaparib combined with bevacizumab in the treatment of advanced colorectal cancer
Yi-Ling Jiang, Xue-Yuan Fu, Zhi-Hui Yin
Yi-Ling Jiang, Department of Oncology, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang 421001, Hunan Province, China
Xue-Yuan Fu, Zhi-Hui Yin, Department of Anorectal, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang 421001, Hunan Province, China
Author contributions: Jiang YL drafted the manuscript; Jiang YL and Fu XY collected and analyzed the clinical data; Yin ZH designed the study, reviewed and revised the manuscript; and all authors have read and approved the final manuscript.
Institutional review board statement: The study was approved by the Ethics Committee of The First Affiliated Hospital, Hengyang Medical School, University of South China.
Informed consent statement: The data used in this study were not involved in the patients’ private information, so the informed consent was waived by the Ethics Committee of The First Affiliated Hospital, Hengyang Medical School, University of South China. All patient data obtained, recorded and managed are only used for this study, and all patient information is strictly confidential, without any harm to the patient.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Zhi-Hui Yin, MM, Associate Chief Physician, Department of Anorectal, The First Affiliated Hospital, Hengyang Medical School, University of South China, No. 69 Chuanshan Avenue, Shigu District, Hengyang 421001, Hunan Province, China. yinzhihui6996@163.com
Received: February 19, 2023 Peer-review started: February 19, 2023 First decision: March 1, 2023 Revised: March 11, 2023 Accepted: April 7, 2023 Article in press: April 7, 2023 Published online: May 27, 2023 Processing time: 95 Days and 23.3 Hours
Core Tip
Core Tip: Colorectal cancer (CRC) presents insignificant symptoms in the early stage and is commonly diagnosed in the middle and advanced stages. Therefore, surgery is usually not viable because the best timing is missed, and chemotherapy, targeted therapies and other regimens are often utilized as interventions. Olaparib and bevacizumab are common targeted therapies with excellent therapeutic effects in a variety of solid tumors. This research collected the clinical data of 82 patients with advanced CRC, retrospectively investigated the clinical efficacy and safety of olaparib combined with bevacizumab in advanced CRC treatment, and analyzed the effect of this treatment regimen on the serum levels of vascular endothelial growth factor, matrix metalloprotein-9, cyclooxygenase-2, and related tumor markers.
